BiomEdit LLC

BOSTON, April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its 5th annual Ferment conference. The conference brings together stakeholders from across the synthetic biology community, including R&D leaders, Ginkgo Technology Network partners, experts from across academia, journalists, and many more. Because the event has reached its in-person capacity limits, a livestream will be available on Ginkgo's YouTube page and Ginkgo's Investor Relations page. Continue Reading Ginkgo Ferment 2024 Ferment will begin with a keynote address from Ginkgo co-founder and CEO, Jason Kelly, who will discuss the value that customers across industries can create on Ginkgo's platform, whether they're engaging in end-to-end cell engineering programs or are leveraging Ginkgo's new Lab Data as a Service product. His keynote will describe Ginkgo's progress in building out the Foundry, Codebase, and AI assets which comprise its powerful horizontal platform, and which can help customers unleash the full power of their R&D teams using Ginkgo's services. Jason Kelly, CEO and co-founder, Ginkgo Bioworks: "AI is rapidly changing how all of us think about biological research. The ingredient that's missing is high-quality data, and we're so excited to make the data factory we've built, and are continuing to scale, available to scientists across the industry. Our scientists already have access to these best-in-class services, and now we're opening them up to you, so you can get better data, better models, and better bioengineering." Platform Presentations Ginkgo's technical experts will share more details about platform developments and services throughout the day at Ferment. Ginkgo's General Manager of Biosecurity, Matt McKnight, will introduce Ginkgo Biosecurity, the evolution of Concentric by Ginkgo, which is building and deploying the next-generation biosecurity infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. Matt McKnight, General Manager of Biosecurity, Ginkgo Bioworks: "I'm so excited to share our keystone products with the world today. Biological risk, whether natural or manmade, is increasing across the board, but we have the power to change the calculus. Ginkgo Canopy, our radar for biological anomalies, tracks the emergence and evolution of biological threats for early warning and deep insight. It's always-on, pervasive, and can be tuned to detect a large and growing set of pathogen targets, to help leaders worldwide understand the biological risks that are closest to home. And with Ginkgo Horizon, we can generate actionable biological intelligence that integrates insights from the global network of Canopy biomonitoring with our digital open-source intelligence and AI-powered modeling tools to help those leaders get the decision support they need. All of these capabilities will come together in CUBE-D, our first flagship biosecurity facility in Doha." Ginkgo's co-founder and CTO, Barry Canton, will take the stage for a technical keynote featuring technical leaders from across Ginkgo's platform, including Will Serber (Head of Automation), Emily Wrenbeck (Head of Protein Engineering), Uri Laserson (Senior Director of AI Research), and Shawdee Eshghi (Senior Director of Mammalian Engineering) to discuss Ginkgo's strides in data generation and model training for AI across a range of applications. Barry Canton, CTO and co-founder, Ginkgo Bioworks: "Data is the limiting reagent for AI. When it comes to biology, data is the key ingredient for standing up foundation models and making use of fine-tuned models. You need enormous data sets for the former, and rapid access to high-quality, lab-in-the-loop data generation for the latter. We're very excited to share our progress in making both of these offerings available to our customers so they can make the most of this revolution in biological R&D." Lightning Talks Hear from developers using the Ginkgo platform to build new applications, including: Cradle (Stef van Grieken, CEO) ImaginDairy (Arie Abo, co-founder and CSO) Centrient (Limber Acosta, Director of Innovation & Technology) Light.bio (Keith Wood, CEO) Verb Biotics (Todd Beckman, CEO) Bayer Crop Science (Benoit Hartmann, Head of Biologics) Factorial Biotechnologies (John Wells, founder and CEO) Microba (Trent Munro, Senior Vice President of Therapeutics) OneOne Biosciences (Julien Sylvestre, founder and CEO) Allonnia (Nicole Richards, CEO) GreenLab (Stephen Lallo, Director of Corporate Development) Bioweg (Prateek Mahalwar, founder and CEO) BiomEdit (Aaron Schact, CEO) AQUA Cultured Foods (Stefan K. Baier, CSO) Zymtronix (Stéphane Corgié, founder and CEO) Vivici (Stephan van Sint Fiet, CEO) Sumitomo Chemica (Satoshi Okamoto, Chief Research Coordinator, Corporate Planning Office) Ayana Bio (Weslee Glenn, Vice President of Innovation) Ginkgo's customers will speak to the strides they have made by leveraging Ginkgo's platform to supercharge their biological R&D and accelerate everything from the design to development to commercialization of their products. This newly announced progress includes the achievement of a major milestone, ahead of schedule, in a previously announced program on nitrogen fixation between Ginkgo and Bayer. Benoit Hartmann, Head of Biologics at Bayer Crop Sciences: "We have our eyes set on realizing a bigger future for biologicals by leveraging open innovation through partners like Ginkgo, who are using the power of synthetic biology to change agriculture for the better. Whether it's crop protection, nitrogen optimization, or carbon sequestration, the potential for these innovations for growers and communities worldwide is massive. The important scientific progress we have seen coming out of our nitrogen fixation program enables that better future, and will help us deliver the next generation of biologicals." Jennifer Wipf, Chief Commercial Officer, Ginkgo Bioworks: "It's always such a thrill to see so many of our partners and colleagues under one roof at Ferment. The ingenuity and drive they bring to product innovation and commercialization has always been the inspiration for what we do. Like so many of us across the team, I know what it's like to be in their shoes and to be sitting across the table from R&D vendors and need a solution that just doesn't exist. That's the gap we're closing with our service offerings at Ginkgo, and we're just getting started." The day's programming will also include a series of panels and discussions: Beyond Bits and Bases: AI's Path to Unlocking the Mysteries of Biology Moderator: Anna Marie Wagner (Head of AI and SVP, Corporate Development, Ginkgo Bioworks) Panelists: Karen Akinsanya, PhD (President of R&D, Therapeutics, Schrödinger) Iya Khalil, PhD (Vice President and Head of Data, AI and Genome Sciences, Merck) Molly Gibson, PhD (Origination Partner, Flagship Pioneering, and co-founder & Chief innovation Officer, Generate Biomedicines) Deborah S. Marks, PhD (Professor of Systems Biology, Harvard Medical School) Global Biosecurity in Practice Moderator: Alison Snyder (Managing Editor, Axios) Panelists: Cindy Friedman, MD (Founding Director, CDC's Traveler-Based Genomic Surveillance Program) Wilmot James, PhD (Professor of Practice in Health Policy Services and Practice & Senior Advisor for Pandemics and Global Health Security at the School of Public Health, Brown University) Nikki Romanik (Special Assistant to the President, Deputy Director and Chief of Staff for the Office of Pandemic Preparedness and Response Policy) Productivity Redefined: Paving the Way to Sustainable Pharma Innovation Marcus Schindler, PhD (Executive Vice President & Chief Scientific Officer, Novo Nordisk) Jennifer Wipf (Chief Commercial Officer, Ginkgo Bioworks) Fireside Chat with Renee Wegrzyn and Jon Terrett Moderator: Michael Specter (Staff Writer, The New Yorker & Visiting Scholar, MIT Media Lab) Panelists: Jon Terrett, PhD (Head of Research, CRISPR Therapeutics) Renee Wegrzyn, PhD (Director, Advanced Research Projects Agency for Health) Building Biological Worlds: A Conversation About the Future with the Creators of "Vesper" Moderator: Christina Agapakis, PhD (Senior Vice President of Creative & Marketing, Ginkgo Bioworks) Panelists: Kristina Buožytė (Director, Vesper, and CEO, Natrix Natrix) Alexis Perrin (Producer, Vesper & founder, Rumble Fish Productions) Bruno Samper (Director, Vesper & co-founder and CEO, Nedd) The full event schedule can be found at . A video livestream of the event will also be made available to the public, including on the company's investor relations website at . About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. Ginkgo Bioworks Investor Contact: [email protected] Ginkgo Bioworks Media Contact: [email protected] Forward-Looking Statements of Ginkgo Bioworks This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) the outcome of any pending or potential legal proceedings against Ginkgo, (vii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (viii) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (ix) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 29, 2024 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. SOURCE Ginkgo Bioworks

本期看点 ① 辉凌制药与PharmaBiome达成合作，推进活菌药发展 ② ExeGi管线药物EXE-346 PROF研究首例患者完成入组 ③ Alveolus Bio与BiomEdit达成战略合作 ④ 奥利巴斯与索尼达成新内窥镜业务合作 ⑤ 明治计划投资3.31亿美元在北海道建新厂 ⑥ Clever Carnivore完成700万美元种子轮融资 ① 辉凌制药与PharmaBiome达成合作，推进活菌药发展 作者： 解读：617 来源：Biospace 发布日期：2023-12-11 ■ 内容要点 12月11日，辉凌制药（Ferring Pharmaceuticals）宣布，与总部位于苏黎世的微生物组转化公司PharmaBiome展开合作，以推动活体生物药在胃肠道领域的发展。 该交易将使辉凌制药获得开发、制造和商业化来自于PharmaBiome公司的下一代微生态疗法的独家权利。交易的相关财务细节未披露。 PharmaBiome公司基于其核心技术，开发了一个独特的技术平台，用于快速选择和培养细菌菌株，以设计具有活性的活体生物药产品。PharmaBiome公司旨在开发独立于供体的新一代活体生物药，以准确提供具有所需活性和治疗效果的多菌株活体生物药。 辉凌制药是首家向美国患者推出获FDA批准的活体生物药的公司。2023年2月14日，其旗下基于粪菌的药物REBYOTA（RBX2660）正式在美国上市。REBYOTA是FDA批准的第一个基于微生物组的治疗方法，旨在用于预防18岁及以上个体发生复发性艰难梭菌感染。 原文链接： https://www.biospace.com/article/releases/ferring-and-pharmabiome-enter-into-a-new-microbiome-r-and-amp-d-collaboration-and-exclusive-licensing-agreement/ ② ExeGi管线药物EXE-346 PROF研究首例患者完成入组 作者：ExeGi Pharma 解读：Richard 来源：PR newswire 发布日期：2023-12-08 ■ 内容要点 12月8日，活体生物药公司ExeGi Pharma宣布，旗下管线药物EXE-346的PROF研究首例患者完成入组。 研究旨在评估EXE-346缓解溃疡性结肠炎（UC）患者进行全结直肠切除联合回肠储袋肛管吻合术（Ileal Pouch-anal Anastomosis，IPAA）后排便次数过多的问题。 UC是发生于结肠和直肠黏膜的慢性炎症性疾病，大部分UC患者能够通过内科治疗有效控制病情，但仍有15%-30%的UC患者需要手术治疗。IPAA是UC患者的首选手术治疗方式，部分患者在进行IPAA后出现频繁排便现象。 在研管线EXE-346是一种口服活体生物药，含有8种不同的高活性菌株，并且按照cGMP标准生产。目前，该管线药物已进展到2期临床阶段。 原文链接： https://www.prnewswire.com/news-releases/exegi-pharma-announces-first-patient-enrollment-in-the-prof-trial-of-exe-346-302009573.html ③ Alveolus Bio与BiomEdit达成战略合作 作者：Alveolus Bio 解读：Richard 来源：PR newswire 发布日期：2023-12-08 ■ 内容要点 12月8日，Alveolus Bio公司宣布与动物保健企业BiomEdit达成了一项战略合作。 双方将分享各自拥有的资源和专长，深入开展微生组研究合作，提升益生菌在各个领域的广泛应用。 合作也彰显了两家公司积极投身基础科学研究的热忱态度。 具体地，Alveolus Bio公司将继续深入研究BiomEdit公司的专有益生菌株组合产品。这些菌株能够发挥抗炎和免疫调节功效，体内研究证实其可以降低机体内禽流感病毒载量。未来，Alveolus Bio公司将探索上述菌株在人体中抗流感病毒功效。 Alveolus Bio公司开发了resMIT药物分子递送技术，可以将活性物质递送至肺部深度区域。BiomEdit公司将利用resMIT技术研究其自有管线产品在宠物呼吸道疾病中的应用。 原文链接： https://www.prnewswire.com/news-releases/alveolus-bio-enters-into-strategic-collaboration-with-biomedit-302009651.html ④ 奥利巴斯与索尼达成新内窥镜业务合作 作者：SEAN WHOOLEY 解读：Richard 来源：Mass Device 发布日期：2023-12-08 ■ 内容要点 12月8日，奥林巴斯宣布与索尼达成了一项新的商业合作， 双方将合力开发胃肠道和呼吸道领域使用的新一代内窥镜系统，特别是内窥镜使用的软件系统。 早在2012年，双方便成立了索尼奥林巴斯医疗解决方案公司，奥林巴斯在透镜和光学技术上的专业优势与索尼在数字成像技术上强大能力结合在了一起，创造出了诸多新的产品和服务，极大助力了医疗保健行业的发展。 合作十多年以来，双方合作推出了世界首款4K超高清外科内窥镜系统、4K 3D ORBERE手术显微镜设备和VISERA ELITE III系统等3款重磅产品，引领了内窥镜行业发展。 原文链接： https://www.massdevice.com/sony-olympus-collab-next-gen-endoscopes/ ⑤ 明治计划投资3.31亿美元在北海道建新厂 作者： 解读：617 来源：FoodTalks 发布日期：2023-12-11 ■ 内容要点 12月7日，日本食品集团明治株式会社宣布， 计划投资480亿日元（约合3.31亿美元）在北海道建设一座新工厂。 工厂面积达230258平方米，将生产脂奶粉、浓缩脱脂奶、黄油、奶油以及乳蛋白等产品，产品将用于零售和B2B等。 明治株式会社是一家总部位于日本的跨国食品公司，成立于1887年，拥有100多年的历史。该公司主要经营食品、饮料、医药和营养品等业务。截至2023年3月31日，该公司共有17290名员工，推出了27种健康意识产品和35种营养食品。未来，明治将整合食品和医药品的技术诀窍，力求为全球各地的人们带来真正的健康水平提升。 原文链接： https://www.just-food.com/news/japans-meiji-to-build-new-y48bn-dairy-plant/?cf-view ⑥ Clever Carnivore完成700万美元种子轮融资 作者： 解读：617 来源：FoodTalks 发布日期：2023-12-11 ■ 内容要点 12月4日，Clever Carnivore公司宣布， 完成700万美元（约合人民币5027万元）种子轮融资。 本轮融资由全球知名替代蛋白行业投资商Lever VC领投，同时还获得了McWin Capital Partners、Thia Ventures、Valo Ventures、Newfund Capital和Stray Dog Capital等投资者的支持。 Clever Carnivore公司的研发由联合创始人美国西北大学范伯格医学院的教授Paul Burridge博士领导，该公司优化了其生长培养基以支持其独特的细胞系，从而实现了细胞培养基成本的降低。 Clever Carnivore公司计划在年底前将其林肯公园业务搬迁到附近更大的工厂，使该公司能够将生产扩大到500L的生物反应器，并增加测试厨房。Clever Carnivore公司目前正在生产培养猪肉香肠，并计划在2024年初推出其原型产品Clever Bratwurst。 原文链接： https://www.foodtalks.cn/flash/18261

DUBLIN, July 4, 2023 /PRNewswire/ -- The "Human Drugs for Veterinary Use Market - Forecasts from 2023 to 2028" report has been added to ResearchAndMarkets.com's offering. The human drugs for veterinary use market is expected to grow at a CAGR of 2.90% from US$3.357 billion in 2021 to US$4.102 billion by 2028. Animals are being treated with human medications, which may have the same effects on them as they do on humans. While drugs are tested on animals for human use, these consequences are known. Pharmaceutical companies produce more medications for humans than for animals. Additionally, physicians treat animals with extra-label human medicines due to the disparity in industry sales and growth. The painkillers gabapentin and pregabalin (Lyrica), used off-label in dogs and horses, are examples of human-labeled pharmaceuticals that are frequently recommended in veterinary medicine. Additionally used are narcotics such as fentanyl, morphine, methadone, hydromorphone, ketamine, buprenorphine, and hydrocodone. Tramadol can also be employed; however, because of differences in animal metabolism, bigger doses for animals are prescribed than for humans. Moreover, the rising prevalence of chronic diseases in animals, the growing population of production animals, and an increase in drug habits among pet and poultry business owners, combined with consistent human population growth, are the factors driving the growth. The trend toward pet ownership is driving the animal health industry. As a result, there will be an increase in demand for animal medicines and drugs. Additionally, increased financing for research initiatives will fuel industry expansion in the ensuing years and beyond. Antibiotic resistance is a danger caused by the unnecessary use of antibiotics on healthy animals. With rising health problems like heartworm, diabetes, and cancer, the introduction and spread of drug-resistant diseases threaten the ability to treat animals. Further, the use of parasiticides by pet owners for disease management and prevention is likely to increase as cases of parasite-caused illness in dogs, cats, and other animals rise. For instance, the Pet Food Manufacturers Association (PFMA) reported that 17 million (59%) households in the United Kingdom had pets in 2021, and the PFMA 2022 report predicted that 17.4 million households had pets in 2022. Additionally, the number of dog and cat owners in the United States is 69 million and 45.3 million, respectively, in 2021, as per the American Pet Products Association report. Further, the governments of numerous nations are putting strict laws along with widespread vaccination and drug campaigns. For instance, in January 2022, the regulation on veterinary medicinal products came into effect. It supports the European Union's (EU) action towards antimicrobial resistance (AMR) and new measures for promoting innovation and boosting accessibility and availability to safe and high-quality medications for veterinarians, farmers, and pet owners to manage and prevent animal diseases. The antibiotics segment is expected to hold a considerable market share. By medication, the human drugs for veterinary use market is divided into antibiotics, non-steroidal anti-inflammatories, opioid pain relievers, chemotherapeutics, and others. Factors such as overcrowding in animal production facilities, poor hygiene practices, and the emergence of antibiotic-resistant bacteria have contributed to the higher incidence of infections. According to a study published in Veterinary Microbiology, bacterial respiratory infections are common in livestock, causing economic losses and compromising animal welfare. This has increased the demand for effective antibiotics to combat these infections and safeguard animal health. Moreover, Improved diagnostic techniques, including molecular methods and rapid point-of-care tests, have enhanced the ability to identify and diagnose bacterial infections in animals accurately. This facilitates targeted antibiotic therapy and ensures appropriate treatment. The North American market is expanding because of more veterinary facilities providing reimbursement. By geography, the global human drug for veterinary use market has been classified into North America, South America, Europe, Asia Pacific, and Middle East, and Africa. The trend of growing companionship is increasing in the US, and the consumption of veterinary products is rising further. The United States became a pioneer in recognizing that animals might react similarly to human medicines. Animals are treated with human medications, which have the same effects on them as they do on humans. Animals are treated with human medicines, which have the same impact on them as they do on humans. Although there is a disparity in the production of drugs for animals and humans, there has been a silver lining in treating these diseases with a similar type of drug. In a study by Stanford recently, 98% DNA of a mouse and a human was found to be similar. The possibility of diseases was also found to be identical. Cases of cancer, diabetes, and heart disease were replicas of humans and mice. After that, the study was published, and the US Federal law permitted using human medicines to treat common illnesses in humans and animals. Market Developments: FDA approved the use of penicillin for animals which was earlier used only for humans. In April 2022, Elanco Animal Health Incorporated and Ginkgo Bioworks launched a new company, BiomEdit, to make new and innovative treatment products for animals. Ginkgo Biotech is one of the most successful biotech companies in the US. Key Topics Covered: 1. INTRODUCTION 1.1. Market Overview 1.2. Market Definition 1.3. Scope of the Study 1.4. Market Segmentation 1.5. Currency 1.6. Assumptions 1.7. Base, and Forecast Years Timeline 2. RESEARCH METHODOLOGY 2.1. Research Data 2.2. Research Process 3. EXECUTIVE SUMMARY 3.1. Research Highlights 4. MARKET DYNAMICS 4.1. Market Drivers 4.2. Market Restraints 4.3. Porter's Five Force Analysis 5. HUMAN DRUGS FOR VETERINARY USE MARKET BY MEDICATION TYPE 5.1. Introduction 5.2. Antibiotics 5.3. Non-steroidal anti-inflammatories 5.4. Opioid pain relievers 5.5. Chemotherapeutics 5.6. Others 6. HUMAN DRUGS FOR VETERINARY USE MARKET BY DRUG TYPE 6.1. Introduction 6.2. Penicillin 6.3. Prednisone and Prednisolone 6.4. Diazepam 6.5. Prozac 6.6. Others 7. HUMAN DRUGS FOR VETERINARY USE MARKET BY GEOGRAPHY 7.1. Introduction 7.2. North America 7.2.1. USA 7.2.2. Canada 7.2.3. Mexico 7.3. South America 7.3.1. Brazil 7.3.2. Argentina 7.3.3. Others 7.4. Europe 7.4.1. UK 7.4.2. Germany 7.4.3. France 7.4.4. Italy 7.4.5. Others 7.5. Middle East and Africa 7.5.1. Saudi Arabia 7.5.2. Israel 7.5.3. Others 7.6. Asia Pacific 7.6.1. China 7.6.2. Japan 7.6.3. India 7.6.4. South Korea 7.6.5. Indonesia 7.6.6. Thailand 7.6.7. Taiwan 7.6.8. Others 8. COMPETITIVE ENVIRONMENT AND ANALYSIS 8.1. Major Players and Strategy Analysis 8.2. Emerging Players and Market Lucrativeness 8.3. Mergers, Acquisitions, Agreements, and Collaborations 8.4. Vendor Competitiveness Matrix 9. COMPANY PROFILES 9.1. Merck & Co 9.2. Zoetis 9.3. Boehringer Ingelheim 9.4. Elanco animal health 9.5. Vetoquinol S.A 9.6. Ceva Sante Animale 9.7. Virbac S.A For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets